161 related articles for article (PubMed ID: 34775512)
1. Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1.
Dieckmann KP; Dumlupinar C; Radtke A; Matthies C; Pichler R; Paffenholz P; Sommer J; Winter A; Zengerling F; Hennig F; Wülfing C; Belge G
World J Urol; 2022 Feb; 40(2):317-326. PubMed ID: 34775512
[TBL] [Abstract][Full Text] [Related]
2. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
3. Testicular neoplasms: the interrelationships of serum levels of microRNA-371a-3p (M371) and classical tumor markers with histology, clinical staging, and age-a statistical analysis.
Dieckmann KP; Dumlupinar C; Grobelny F; Utschig J; Klemke M; Ahmed Saad EM; Wülfing C; Pichlmeier U; Isbarn H; Belge G
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7079-7090. PubMed ID: 36869885
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin.
Belge G; Grobelny F; Radtke A; Bodes J; Matthies C; Wülfing C; Dieckmann KP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):435-443. PubMed ID: 33200255
[TBL] [Abstract][Full Text] [Related]
5. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
Belge G; Dumlupinar C; Nestler T; Klemke M; Törzsök P; Trenti E; Pichler R; Loidl W; Che Y; Hiester A; Matthies C; Pichler M; Paffenholz P; Kluth L; Wenzel M; Sommer J; Heinzelbecker J; Schriefer P; Winter A; Zengerling F; Kramer MW; Lengert M; Frey J; Heidenreich A; Wülfing C; Radtke A; Dieckmann KP
Clin Cancer Res; 2024 Jan; 30(2):404-412. PubMed ID: 37967143
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
7. Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours.
Dieckmann KP; Grobelny F; Soave A; Che Y; Nestler T; Matthies C; Heinzelbecker J; Winter A; Heidenreich A; Niemzok T; Dumlupinar C; Angerer M; Wülfing C; Paffenholz P; Belge G
Eur Urol Focus; 2024 May; ():. PubMed ID: 38729824
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
9. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
10. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
11. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid.
Dieckmann KP; Spiekermann M; Balks T; Ikogho R; Anheuser P; Wosniok W; Loening T; Bullerdiek J; Belge G
Urol Int; 2016; 97(1):76-83. PubMed ID: 26989896
[TBL] [Abstract][Full Text] [Related]
13. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
[TBL] [Abstract][Full Text] [Related]
14. Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates-A Comprehensive Statistical Analysis.
Dieckmann KP; Isbarn H; Grobelny F; Dumlupinar C; Utschig J; Wülfing C; Pichlmeier U; Belge G
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358866
[TBL] [Abstract][Full Text] [Related]
15. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment.
Dieckmann KP; Simonsen-Richter H; Kulejewski M; Anheuser P; Zecha H; Isbarn H; Pichlmeier U
Biomed Res Int; 2019; 2019():5030349. PubMed ID: 31275973
[TBL] [Abstract][Full Text] [Related]
16. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the M371-Test Under Real-life Conditions for Diagnosis and Follow Up of Testicular Germ Cell Tumors.
Pycha S; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Palermo M; Pycha A; Danuser H; Trenti E
Anticancer Res; 2023 Apr; 43(4):1649-1653. PubMed ID: 36974797
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
19. The present and future of serum diagnostic tests for testicular germ cell tumours.
Murray MJ; Huddart RA; Coleman N
Nat Rev Urol; 2016 Dec; 13(12):715-725. PubMed ID: 27754472
[TBL] [Abstract][Full Text] [Related]
20. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours.
Bagrodia A; Savelyeva A; Lafin JT; Speir RW; Chesnut GT; Frazier AL; Woldu SL; Margulis V; Murray MJ; Amatruda JF; Lotan Y
BJU Int; 2021 Jul; 128(1):57-64. PubMed ID: 33124175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
